Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation
Search: search_blue_button Advanced Search
Published Online
on November 5, 2007

Circulation. 2007
Published online before print November 5, 2007, doi: 10.1161/CIRCULATIONAHA.107.726950
A more recent version of this article appeared on November 20, 2007
This Article
Right arrow Full Text (PDF)
Right arrow CME: Take the course for this article:
Circulation: November 20, 2007, Volume 116, Number 21
Right arrow All Versions of this Article:
116/21/2366    most recent
CIRCULATIONAHA.107.726950v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Crotti, L.
Right arrow Articles by Crimi, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Crotti, L.
Right arrow Articles by Crimi, G.
Related Collections
Right arrow Arrhythmias, clinical electrophysiology, drugs
Right arrow Genetics of cardiovascular disease
Right arrowRelated Article

Submitted on April 18, 2007
Accepted on August 28, 2007

The Common Long-QT Syndrome Mutation KCNQ1/A341V Causes Unusually Severe Clinical Manifestations in Patients With Different Ethnic Backgrounds. Toward a Mutation-Specific Risk Stratification

Lia Crotti MD, Carla Spazzolini DVM, Peter J. Schwartz MD*, Wataru Shimizu MD, Isabelle Denjoy MD, Eric Schulze-Bahr MD, Elena V. Zaklyazminskaya MD, PhD, Heikki Swan MD, Michael J. Ackerman MD, PhD, Arthur J. Moss MD, Arthur A.M. Wilde MD, Minoru Horie MD, Paul A. Brink MD, PhD, Roberto Insolia PhD, Gaetano M. De Ferrari MD, and Gabriele Crimi MD

From the Section of Cardiology, Department of Lung, Blood and Heart, University of Pavia, Pavia, Italy (L.C., C.S., P.J.S., G.C.); Department of Cardiology (L.C., C.S., P.J.S., G.M.D.F., G.C.) and Molecular Cardiology Laboratory (L.C., P.J.S., R.I.), IRCCS Fondazione Policlinico S. Matteo, Pavia, Italy; Department of Medicine, University of Stellenbosch, South Africa (P.J.S., P.A.B.); Laboratory of Cardiovascular Genetics, IRCCS Istituto Auxologico, Milan, Italy (P.J.S.); Cardiovascular Genetics Laboratory, Hatter Institute for Cardiovascular Research, Department of Medicine, University of Cape Town, Cape Town, South Africa (P.J.S.); Division of Cardiology, Department of Internal Medicine, National Cardiovascular Center, Osaka, Japan (W.S.); Service de Cardiologie, Hôpital Lariboisière, and Inserm U582, Paris, France (I.D.); Med Klinik und Poliklinik C (Kardiologie/Angiologie), Molekulare Genetik und Spezialambulanz für Patienten mit angeborenen, arrhythmogenen Erkrankungen, Universitätsklinikum Münster, Münster, Germany (E.S.-B.); Research Center of Medical Genetics, Laboratory of DNA Research, Moscow, Russia (E.V.Z.); Helsinki University Hospital, Department of Cardiology, Helsinki, Finland (H.S.); Departments of Medicine, Pediatrics, and Molecular Pharmacology and Experimental Therapeutics, Divisions of Cardiovascular Diseases and Pediatric Cardiology, Mayo Clinic College of Medicine, Rochester, Minn (M.J.A.); Cardiology Division, Department of Medicine, University of Rochester Medical Center, Rochester, NY (A.J.M.); Departments of Cardiology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands (A.A.M.W.); and Department of Cardiology, Shiga University of Medical Sciences, Ohtsu, Japan (M.H.).

* To whom correspondence should be addressed. E-mail: pjqt{at}compuserve.com.

Background—The impressive clinical heterogeneity of the long-QT syndrome (LQTS) remains partially unexplained. In a South African (SA) founder population, we identified a common LQTS type 1 (LQT1)–causing mutation (KCNQ1-A341V) associated with high clinical severity. We tested whether the arrhythmic risk was caused directly by A341V or by its presence in the specific ethnic setting of the SA families.

Methods and Results—Seventy-eight patients, all with a single KCNQ1-A341V mutation, from 21 families and 8 countries were compared with 166 SA patients with A341V and with 205 non-A341V LQT1 patients. In the 2 A341V populations (SA and non-SA), the probability of a first event through 40 years of age was similar (76% and 82%), and the QTc was 484±42 versus 485±45 ms (P=NS). Compared with the 205 non-A341V patients with the same median follow-up (30 versus 32 years), the 244 A341V patients were more likely to have cardiac events (75% versus 24%), were younger at first event (6 versus 11 years), and had a longer QTc (485±43 versus 465±38 ms) (all P<0.001). Arrhythmic risk remained higher (P<0.0001) even when the A341V patients were compared with non-A341V patients with mutations either localized to transmembrane domains or exhibiting a dominant-negative effect. A341V patients had more events despite {beta}-blocker therapy.

Conclusions—The hot spot KCNQ1-A341V predicts high clinical severity independently of the ethnic origin of the families. This higher risk of cardiac events also persists when compared with LQT1 patients with either transmembrane or dominant-negative mutations. The identification of this high-risk mutation and possibly others may improve the risk stratification and management of LQTS.


Key words: arrhythmia • death, sudden • genetics • long-QT syndrome • risk factors


Related Article:

Issue Highlights
Circulation 2007 116: 2359. [Extract] [Full Text]



This article has been cited by other articles:


Home page
CirculationHome page
L. Crotti, M. C. Monti, R. Insolia, A. Peljto, A. Goosen, P. A. Brink, D. A. Greenberg, P. J. Schwartz, and A. L. George Jr
NOS1AP Is a Genetic Modifier of the Long-QT Syndrome
Circulation, October 27, 2009; 120(17): 1657 - 1663.
[Abstract] [Full Text] [PDF]


Home page
Heart AsiaHome page
R J Sung and N-Y Chan
Practice viewpoints: AICD, who and when?
Heart Asia, October 15, 2009; 2009(10): 7 - 9.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart JHome page
G. M. De Ferrari and P. J. Schwartz
Long QT syndrome, a purely electrical disease? Not anymore
Eur. Heart J., February 1, 2009; 30(3): 253 - 255.
[Full Text] [PDF]


Home page
Circ Arrhythm ElectrophysiolHome page
A. J. Moss and I. Goldenberg
Importance of Knowing the Genotype and the Specific Mutation When Managing Patients With Long-QT Syndrome
Circ Arrhythm Electrophysiol, August 1, 2008; 1(3): 219 - 226.
[Full Text] [PDF]


Home page
Circ Arrhythm ElectrophysiolHome page
G. M. Vincent
Genotyping Has a Minor Role in Selecting Therapy for Congenital Long-QT Syndromes at Present
Circ Arrhythm Electrophysiol, August 1, 2008; 1(3): 227 - 233.
[Full Text] [PDF]


Home page
J Am Coll CardiolHome page
I. Goldenberg and A. J. Moss
Long QT syndrome.
J. Am. Coll. Cardiol., June 17, 2008; 51(24): 2291 - 2300.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
P. J. Schwartz, E. Vanoli, L. Crotti, C. Spazzolini, C. Ferrandi, A. Goosen, P. Hedley, M. Heradien, S. Bacchini, A. Turco, et al.
Neural control of heart rate is an arrhythmia risk modifier in long QT syndrome.
J. Am. Coll. Cardiol., March 4, 2008; 51(9): 920 - 929.
[Abstract] [Full Text] [PDF]